Dec 30, 2025 • The AI Journal
NEUTRAL
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi, questioning the adequacy of the $221.50 per share cash consideration for Cidara shareholders and the process leading to the transaction. KSF is urging shareholders who believe the offer undervalues the company to contact them to discuss their legal rights. The firm emphasizes the time-sensitive nature of the tender offer structure.
Dec 29, 2025 • MLex
BULLISH
Sanofi agrees to acquire DynaVax for $2.2 bln, adds hepatitis B vaccine
Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion, a deal expected to close in Q1 2026. This acquisition will add Dynavax's adult hepatitis B vaccine, HEPLISAV-B®, and a shingles vaccine candidate, Z-1018, to Sanofi's portfolio. The transaction enhances Sanofi's vaccine offerings with a currently marketed product and a promising pipeline candidate.
Dec 29, 2025 • TradingView — Track All Markets
BULLISH
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi
Dynavax Technologies has entered into an Agreement and Plan of Merger with Sanofi, under which Sanofi will acquire Dynavax. Sanofi plans to launch a cash tender offer of $15.50 per share for all Dynavax shares, followed by a merger that will make Dynavax a wholly-owned subsidiary. The transaction aims to provide immediate cash value to shareholders and integrate Dynavax into Sanofi's global platform.
Dec 28, 2025 • Insider Monkey
BULLISH
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)
Sanofi (NASDAQ: SNY) announced a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ: DVAX) for $15.50 per share in cash, valuing the deal at approximately $2.2 billion in equity. This acquisition aims to expand Sanofi's adult immunization presence, specifically leveraging Dynavax's marketed hepatitis B vaccine, HEPLISAV-B, and a shingles vaccine candidate. The deal, unanimously approved by Dynavax's board, is expected to close in Q1 2026 and will not impact Sanofi's 2025 financial guidance.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Exchange Traded Concepts LLC Has $2 Million Stake in Dynavax Technologies Corporation $DVAX
Exchange Traded Concepts LLC significantly increased its stake in Dynavax Technologies Corporation by 50.4% in Q3, bringing its holdings to 200,976 shares valued at approximately $1.996 million. The biopharmaceutical company recently beat earnings estimates with $0.21 EPS on $94.88 million revenue, though it maintains a negative net margin and P/E ratio. Institutional ownership remains high at 96.96%, with analysts giving the stock a "Hold" consensus rating and a $24.33 price target.
Dec 26, 2025 • FinancialContent
SOMEWHAT-BULLISH
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
Dynavax Technologies Corporation (NASDAQ: DVAX) has been acquired by Sanofi (NASDAQ: SNY) for $2.2 billion, marking a significant turnaround for the biotech company. Once plagued by clinical setbacks, Dynavax pivoted its focus to become a leader in adult vaccines, primarily driven by its HEPLISAV-B Hepatitis B vaccine and CpG 1018 adjuvant. This acquisition validates Dynavax's strategic shift and successful commercialization efforts, providing Sanofi with a strong foothold in the growing adult immunization market.